An Oral PCSK9 Inhibitor — Coming Soon?

Crawford, Michael H. MD, Editor

Clinical Cardiology Alert 42(5):p 39-40, May 2023.

SYNOPSIS:

A Phase IIb study of four doses of MK-0616, an orally administered PCSK9 inhibitor, compared to placebo showed significant reductions in LDL cholesterol levels without any differences in adverse effects over eight weeks.

SOURCE:

Ballantyne CM, Banka P, Mendez G, et al. Efficacy and safety of the oral PCSK9 inhibitor MK-0616: A phase 2b randomized controlled trial. J Am Coll Cardiol 2023; Feb 16: S0735-1097(23)00412-6. doi: 10.1016/j.jacc.2023.02.018. [Online ahead of print].